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http://dxObjective: Ventricular fibrillation occurs commonly after aortic crossclamping in patients undergoing cardiac
surgery. Ventricular fibrillation increases myocardial oxygen consumption, and defibrillation may harm the
myocardium. Thus, a pharmacologic approach to decreasing the incidence of ventricular fibrillation or the num-
ber of shocks required may be beneficial. The goal of this study was to evaluate whether amiodarone or lidocaine
was superior to placebo for the prevention of ventricular fibrillation after aortic crossclamping in patients un-
dergoing a variety of cardiac surgical procedures.
Methods: Patients undergoing cardiac surgery requiring aortic crossclamping were randomized to receive lido-
caine 1.5 mg/kg, amiodarone 300 mg, or placebo before aortic crossclamp removal The primary outcomes were
the incidence of ventricular fibrillation and the number of shocks required to terminate ventricular fibrillation.
Results: A total of 342 patients completed the trial. On multivariate analysis, there was no difference in the in-
cidence of ventricular fibrillation among treatment groups. The number of required shocks was categorized as 0,
1 to 3, and greater than 3. On multivariate analysis, patients receiving amiodarone required fewer shocks to ter-
minate ventricular fibrillation (odds ratio, 0.51; 95% confidence interval, 0.31-0.83; P¼ .008 vs placebo). There
was no difference between lidocaine and placebo in the number of required shocks (odds ratio, 0.86; 95% con-
fidence interval, 0.52-1.41; P ¼ .541).
Conclusions: In patients undergoing a variety of cardiac surgical procedures, neither amiodarone nor lidocaine
reduced the incidence of ventricular fibrillation. Amiodarone decreased the number of shocks required to termi-
nate ventricular fibrillation. (J Thorac Cardiovasc Surg 2012;144:1229-34)The incidence of ventricular fibrillation (VF) after release
of the aortic crossclamp in patients undergoing cardiac sur-
gery has been reported to be between 45% and 100%.1-7
Multiple mechanisms have been proposed to explain the
high incidence of VF, including ischemia-mediated in-
creases in reentry, automaticity, and reperfusion injury.8-10
VF may result in increased myocardial oxygen
consumption, distension of the ventricle with resultant
increases in wall tension, and acidosis of the myocardial
tissue.11-14 These changes may be particularly pronounced
in the hypertrophied ventricle when the mean arterial
blood pressure is less than 50 to 60 mm Hg.15-17e Department of Anesthesiology,a Department of Biomedical Statistics and
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P
MAlthough VF is known to adversely affect the heart, the
‘‘gold standard’’ treatment, internal direct-current shock,
also may be harmful. Animal models using monophasic
damped sine waveform shocks suggest that defibrillation
leads to decreased myocardial performance and micro-
scopic damage to myocytes and that the injury is more pro-
nounced with repeated shocks with a short time interval
between shocks.18,19 Given these findings, the prevention
of reperfusion VF or a decrease in the number of
defibrillation attempts required to terminate VF may be
of benefit in preserving myocardial function after
cardiopulmonary bypass (CPB).
Lidocaine, a class I (sodium channel blocking) antiar-
rhythmic drug, has a long history of use in cardiac surgery
for the prevention of VF. Several studies have shown its effi-
cacy in preventing VF and decreasing the number of shocks
required to defibrillate VFwhen it does occur.1-5,20 However,
all of these studies have been performed in relatively
homogeneous patient populations, that is, patients
undergoing coronary artery bypass grafting (CABG).
Intravenous amiodarone has multiple mechanisms of
action, including blockade of potassium, sodium, and
calcium channels, as well as alpha and beta adrenergic
antagonism.21 Amiodarone has been well studied in the set-
ting of out-of-hospital cardiac arrest. Randomized, blindeddiovascular Surgery c Volume 144, Number 5 1229
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CABG ¼ coronary artery bypass grafting
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Mtrials in adults have shown amiodarone to be superior to both
placebo and lidocaine in the resuscitation of patients withVF
or pulseless ventricular tachycardia.22,23 Other studies have
shown amiodarone to improve the response of VF to
shocks.24,25 To date, 2 studies have evaluated amiodarone
for the prevention of VF after aortic crossclamping with
mixed results.1,6
The goal of the present study was to evaluate whether
amiodarone or lidocaine was superior to placebo for the pre-
vention of VF after aortic crossclamping in patients under-
going a variety of cardiac surgical procedures.
MATERIALS AND METHODS
This randomized, double-blind, placebo-controlled trial was conducted
at Mayo Clinic in Rochester, Minnesota. The study was approved by the
Mayo Foundation Institutional Review Board, and all patients gavewritten,
informed consent. Patients were eligible for inclusion if they were aged
more than 18 years and undergoing an elective cardiac procedure that
was expected to include crossclamping of the aorta.Women of childbearing
agewere included only if they agreed to the use of birth control for at least 5
months after the procedure. Patients were excluded for an allergy to amio-
darone or a history of organ dysfunction due to previous amiodarone use.
Patients were also excluded if it was expected that they would require
more than mild systemic hypothermia (<32C) during CPB. Before opera-
tion, subjects were randomized in a 1:1:1 fashion to receive amiodarone
(group A), lidocaine hydrochloride (group L), or saline (group P) before
aortic crossclamp removal. All study drugs were prepared by a research
pharmacist and diluted to 12 mL total volume. Anesthesiologists, surgeons,
andCPB perfusionists were strictly blinded as to the content of the syringes.
Procedure
After consent was obtained and randomization had occurred, patients
were brought to the operating room. Induction andmaintenance of anesthe-
sia were at the discretion of the anesthesiologist and included the use of
midazolam, sodium thiopental, propofol or ketamine, fentanyl or sufenta-
nil, isoflurane, and pancuronium or vecuronium. Hemodynamic monitor-
ing included the use of an arterial catheter and central venous catheter
with or with or without a pulmonary artery catheter.
The cannulation sites for CPB were at the discretion of the cardiac sur-
geon and dependent on the operation. The aorta was cannulated with a pa-
tient size–appropriate cannula. Venous cannulation was obtained with
a single 2-stage cannula in the right atrium or separate cannulae in the su-
perior and inferior vena cavae. Anticoagulation was initiated with 300 u/kg
of heparin and maintained according to an activated clotting time (Hemo-
chron 801, International Technidyne, Edison, NJ) of more than 500 sec-
onds. Perfusion during CPB used nonpulsatile flow with Sarns 9000
(Terumo Cardiovascular Systems, Ann Arbor, Mich) or Sorin S5 (Sorin,
Munich, Germany) CPB equipment and a Terumo membrane oxygenator.
CPB flows were maintained at 2.0 to 2.4 L$min1$m2. Mean arterial pres-
sure was maintained at 60 to 80 mm Hg during CPB. Hyperkalemic cold
blood cardioplegia was given every 20 to 30 minutes for myocardial1230 The Journal of Thoracic and Cardiovascular Surprotection (Table 1). Cardioplegia consisted of blood mixed with crystal-
loid components in a ratio of 4 parts blood to 1 part crystalloid. The crys-
talloid component consisted of lactated Ringer’s solution with 50 mEq/L of
sodium bicarbonate and either 100 mEq/L (for induction of cardiac arrest)
or 50 mEq/L (for maintenance of cardiac arrest) of potassium. Warm,
potassium-free restorative cardioplegia was not administered before cross-
clamp removal. Septal myocardial temperature readings as a marker of ad-
equacy of cardioplegia delivery were not used.
The surgeon notified the anesthesia and perfusion teams before antici-
pated removal of the aortic crossclamp with a goal of administering the
study drugs approximately 3 minutes (3 circulation times) before cross-
clamp removal. At this time, patients in group A received 300 mg of amio-
darone, patients in group L received 1.5 mg/kg of lidocaine, and patients in
group P received placebo (saline). All study drugs were administered via
the CPB venous reservoir. Patients were not given magnesium sulfate dur-
ing the study period because of potential confounding effects.
If VF occurred after aortic crossclamp removal, patients received up to 3
consecutive rectilinear biphasic waveform shocks using internal paddles
with 10 J of energy (Zoll R Series Defibrillator, Zoll Medical, Chelmsford,
Mass). If defibrillation was unsuccessful after 3 attempts using 10 J, a sec-
ond dose of study medication was administered on the basis of prior ran-
domization. Patients in group A received an additional 150 mg of
amiodarone, patients in group L received 1.5 mg/kg of lidocaine, and pa-
tients in group P received placebo (saline). Defibrillation was again attemp-
ted, but escalating energy levels were used (first shock 10 J, second shock
20 J, and third shock 30 J). As a safety measure, the patient’s randomization
was made immediately available to the team in the operating room after the
second dose of medication. The patient’s group assignment was noted on
paper and delivered in a sealed, opaque envelope with the study drugs to
the operating room. Thus, should VF persist after the second dose of study
medication and second set of shocks, the envelope could be immediately
opened and the entire team would be aware of what medications had al-
ready been administered. At this point, further therapy was at the discretion
of the consultant anesthesiologist and surgeon.
Outcome Measurements
Patient demographics were recorded and included age, medical comor-
bidities, current medication use, left ventricular ejection fraction, type of
operation, duration of CPB, duration of aortic crossclamping, and times
of cardioplegia administration. Two primary outcomes were compared
among the 3 study groups: (1) the incidence ofVF after removal of the aortic
crossclamp and (2) the number of defibrillations required to terminate VF.
In addition, we sought to determine the relationship between left ven-
tricular mass and the incidence of VF after aortic crossclamp removal.
To this end, the patients’ charts were manually reviewed by a single,
blinded investigator and recorded left ventricular mass as obtained from
a transthoracic echocardiogram performed at the Mayo Clinic within 1
year of operation.Sample Size
On the basis of the available literature, the expected overall incidence of
VF after removal of the aortic crossclamp is approximately 70%. By using
a chi-square test with 80% power and an alpha of 0.0167 to adjust for mul-
tiple comparisons (given the total of 3 comparisons, 0.05/3 ¼ 0.0167 was
used in the calculation.), we estimated that we would need 113 patients in
each group to show a 30% reduction in the incidence of VF with amiodar-
one. Given the potential for patient dropouts, we planned to enroll 120
patients in each group for a total study population of 360 patients.Statistical Methods
All data including primary and secondary outcome datawere analyzed on
the basis of the intention to treat principle. Categoric baseline characteristics
and outcomes were compared between groups using chi-square tests orgery c November 2012
TABLE 1. Demographics
Control
n ¼ 112
Lidocaine
n ¼ 115
Amiodarone
n ¼ 115
P
value
Age (y) 63.6  13.0 62.7  13.9 63.3  13.6 .91
Height (cm) 174  10.2 172.9  10.2 171  10.2 .039
Weight (kg) 91.2  20.8 88.1  19.5 86.9  18.4 .429
Gender
Male 82 (73.2%) 81 (70.4%) 74 (64.3%) .333
Female 30 (26.8%) 34 (29.6%) 41 (35.7%)
Left ventricular ejection fraction (%) 62.8  11.7 62.7  11.5 62.7  10.8 .862
Procedure
CABG only 20 (17.9%) 15 (13.0%) 18 (15.7%) .806
Valve only 31 (27.7%) 37 (32.2%) 38 (33.0%)
Septal myectomy 34 (30.4%) 30 (26.1%) 34 (29.6%)
Multiple procedures 27 (24.1%) 33 (28.7%) 25 (21.7%)
Medical history
Diabetes mellitus 14 (12.5%) 14 (12.2%) 16 (13.9%) .916
Coronary artery disease 45 (40.2%) 41 (35.7%) 42 (36.5%) .757
Current smoker 9 (8.0%) 11 (9.6%) 7 (6.1%) .618
COPD 5 (4.5%) 7 (6.1%) 3 (2.6%) .436
Hypertension 48 (42.9%) 37 (32.2%) 55 (47.8%) .048
History of dysrhythmias
Atrial fibrillation 17 (15.2%) 22 (19.1%) 23 (20.0%) .605
Atrial flutter 1 (0.89%) 2 (1.7 (%) 4 (3.5%) .373
Ventricular 3 (2.7%) 3 (2.6%) 0 (0%) .213
Preoperative medications
Beta-blocker 73 (65.2%) 73 (63.5%) 67 (58.3%) .532
ACEI/ARB 29 (25.9%) 31 (27.0%) 43 (37.4%) .112
Statin 60 (53.6%) 42 (36.5%) 46 (40.0%) .024
Digoxin 7 (6.3%) 4 (3.5%) 7 (6.1%) .574
Amiodarone 2 (1.8%) 7 (6.1%) 5 (4.3%) .259
Duration of aortic crossclamp (min) 53.3  36.8 46.5  56.1 47.4  32.1 .447
Duration of CPB (min) 78.0  48.7 74.3  40.0 70.8  64.0 .444
Time between cardioplegia administrations (min) 21.0  9.1 20.8  8.9 21.4  9.3 .956
Time from study drug administration to crossclamp removal (min) 3.2  7.6 3.0  5.6 3.6  5.4 .415
Data are presented as mean  standard deviation for continuous variables and n (%) for categoric variables. CABG, Coronary artery bypass grafting; COPD, chronic obstructive
pulmonary disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CPB, cardiopulmonary bypass.
Mauermann et al Perioperative ManagementFisher exact test (where appropriate), whereas continuous variables were
compared using analysis of variance or Kruskal–Wallis tests (where appro-
priate). Because a few baseline variables were significantly different be-
tween groups (Table 1), normal and ordinal logistic regression models
were used to find univariate and multivariate predictors for VF and number
of shocks. Then, the variable containing the treatment groups was forced in
eachmultivariatemodel to detect the difference after adjusting for confound-
ingvariables. Themultivariablemodel considered all univariately significant
variables (P<.05) with model selection using the stepwise method (back-
ward and forward methods resulted in the same model). All statistical tests
were 2-sided with the alpha level set at 0.05 for statistical significance.P
MRESULTS
A total of 360 patients were enrolled in the trial. Eighteen
patients were excluded after enrollment for protocol viola-
tions, leaving 115 patients in group A, 115 patients in group
L, and 112 patients in group P (Figure 1). A comparison of
patient and procedural characteristics between study groups
is shown in Table 1. Patients in group Awere more likely toThe Journal of Thoracic and Carhave hypertension (47.8% vs 32.2% in group L and 42.9%
in group P; P ¼ .048) and patients in group P were more
likely to be taking a statin medication at the time of surgery
(53.6% vs 36.5% in group L and 40.0% in group A;
P ¼ .024). The mean left ventricular ejection fraction was
normal. Eighteen patients had ejection fractions less than
40%, and these were evenly distributed between study
groups (P ¼ .221) (data not shown).
In total, 196 patients (57.3%) experienced VF after aortic
crossclamp removal. The only univariate predictor of VF
was operation type, with patients undergoing septal myec-
tomy having a higher incidence of VF than patients under-
going CABG (odds ratio [OR], 5.09; 95% confidence
interval [CI], 2.47-10.47; P<.001) (Table 2). In contrast,
advancing age, preoperative digoxin or amiodarone use,
and longer aortic crossclamp and CPB times reduced the oc-
currence of VF. When univariate predictors were placed in
a multivariate model, septal myectomy (OR, 5.59; 95% CI,diovascular Surgery c Volume 144, Number 5 1231
577 patients screened for 
enrollment 
360 patients met enrollment criteria and gave 
consent
115 patients received 
amiodarone 
115 patients received 
lidocaine
112 patients received 
placebo
18 patients excluded in analysis 
1 patient received amiodarone 
before CPB 
     4 patients withdrew enrollment 
2 patients underwent 
hypothermic arrest 
5 patients did not receive the 
study drug 
5 patients did not undergo aortic 
cross clamp 
1 patient had randomization 
broken before completion of 
protocol
FIGURE 1. Flow diagram of patient enrollment and dropouts. CPB, Car-
diopulmonary bypass.
TABLE 3. Multivariate analysis of incidence of ventricular fibrillation
OR 95% CI
P
value
Amiodarone vs placebo 0.65 0.37-1.12 .121
Lidocaine vs placebo 0.85 0.48-1.47 .577
Type of operation
Valve only vs CABG 2.12 1.07-4.19 .031
Septal myectomy vs CABG 5.59 2.69-11.26 <.001
Multiple procedures vs CABG 1.98 0.97-4.01 .059
Preoperative amiodarone use 0.24 0.07-0.82 .023
OR, Odds ratio; CI, confidence interval; CABG, coronary artery bypass grafting.
Perioperative Management Mauermann et al
P
M2.69-11.26; P<.001) and valve surgery (OR, 2.12; 95%CI,
1.07-4.19; P¼ .031) became positive predictors of VF. Pre-
operative amiodarone use was protective against VF (OR,
0.24; 95% CI 0.07-0.82; P ¼ .023) (Table 3). There was
no effect of acute administration of amiodarone or lidocaine
on the occurrence of VF.TABLE 2. Univariate analysis of incidence of ventricular fibrillation
after aortic crossclamp removal and number of shocks required to
terminate ventricular fibrillation
Category OR 95% CI
P
value
Incidence of VF after crossclamp remooval
Amiodarone vs placebo 0.65 0.39-1.11 .117
Lidocaine vs placebo 0.80 0.47-1.37 .433
Type of operation
Valve vs CABG 1.92 0.98-3.77 .058
Myectomy vs CABG 5.09 2.47-10.47 <.001
Multiple procedures vs CABG 1.86 0.92-3.74 .083
No. of shocks required
Amiodarone vs placebo 0.51 0.32-0.84 .008
Lidocaine vs placebo 0.82 0.52-1.33 .424
Type of operation
Valve vs CABG 1.97 1.03-3.76 .040
Myectomy vs CABG 3.87 2.00-7.50 <.001
Multiple procedures vs CABG 1.83 0.93-3.58 .078
VF, Ventricular fibrillation; OR, odds ratio; CI, confidence interval; CABG, coronary
artery bypass grafting.
1232 The Journal of Thoracic and Cardiovascular SurFor the outcome of the number of shocks required to ter-
minate VF, patients were categorized as receiving 0, 1 to 3,
or more than 3 shocks. We chose to categorize the number
of shocks because the number of shocks did not follow nor-
mal distribution with 75% of patients requiring 2 or fewer
shocks. Univariate predictors of patients requiring fewer
shocks included receiving amiodarone versus placebo,
older age, preoperative use of amiodarone or digoxin, and
longer duration of CPB. Univariate predictors of patients re-
quiring a larger number of shocks included septal myec-
tomy versus CABG and valve surgery versus CABG
(Table 2). In the multivariate model predicting the number
of shocks required to terminate VF, amiodarone was supe-
rior placebo (OR, 0.51; 95% CI, 0.31-0.83; P ¼ .008). Li-
docaine provided no benefit in reducing the number of
shocks required to terminate VF (OR, 0.86; 95% CI,
0.52-1.41; P ¼ .541). Predictors of an increased number
of shocks required included valve surgery versus CABG,
septal myectomy versus CABG, and multiple combined
procedures versus CABG (Table 4). Preoperative amiodar-
one use decreased the number of shocks required to termi-
nate VF (OR, 0.24; 95% CI, 0.07-0.79; P ¼ .019).
We did attempt a subgroup analysis based on the type of
operation. Patients were divided into groups consisting of
isolated CABG (N ¼ 53), valve surgery (N ¼ 106), septal
myectomy (N ¼ 98), and combined procedures (N ¼ 85).
In this subgroup analysis, neither lidocaine nor amiodarone
decreased the incidence of VF or the number of shocksTABLE 4. Multivariate analysis of number of defibrillations
(categorized into 0, 1-3, and>3)
OR 95% CI
P
value
Amiodarone vs placebo 0.51 0.31-0.83 .008
Lidocaine vs placebo 0.86 0.52-1.41 .541
Type of operation
Valve vs CABG 2.13 1.11-4.09 .024
Septal myectomy vs CABG 3.81 1.98-7.35 <.001
Multiple procedures vs CABG 2.03 1.04-3.96 .038
Preoperative digoxin use 0.39 0.14-1.10 .075
Preoperative amiodarone use 0.24 0.07-0.79 .019
OR, Odds ratio; CI, confidence interval; CABG, coronary artery bypass grafting.
gery c November 2012
Mauermann et al Perioperative Management
P
Mrequired to terminate VF in the specific subsets of patients
(data not shown).
Given the relationship between patients undergoing sep-
tal myectomy and the high incidence of VF, we analyzed the
effect of left ventricular mass on the incidence of VF. A total
of 230 patients had undergone transthoracic echocardiogra-
phy within 1 year before operation. Left ventricular mass
was recorded from the available echocardiography reports.
After adjusting for significant predictors that were found to
affect VF and the need for defibrillatory shocks among the
whole cohort, increasing left ventricular mass was predic-
tive of VF after aortic crossclamp removal (OR, 1.04; CI,
1.01-1.08; P ¼ .009 for every 10-g increase in left
ventricular mass) and the need for increasing number of de-
fibrillatory shocks (OR, 1.05; CI, 1.02-1.08; P<.001 for ev-
ery 10-g increase in left ventricular mass). Given the fact
that left ventricular mass was available for only 230 of
the 342 patients in the study population, left ventricular
mass was not used in the final multivariate models.
DISCUSSION
In this trial of patients undergoing a variety of cardiac surgi-
cal procedures, neither amiodarone nor lidocaine given 3min-
utes before aortic crossclamp removal decreased the incidence
of VF. However, amiodarone, but not lidocaine, decreased the
number of shocks required to terminate VF.
Several studies have shown lidocaine to decrease the in-
cidence of reperfusion VF when compared with control
groups.1-3,5,6 All of these studies were performed in
patients undergoing CABG. Thus, the current trial differs
from these studies in that we included a variety of
surgical procedures, including CABG, valve surgery,
septal myectomy for the treatment of hypertrophic
obstructive cardiomyopathy, and combined procedures.
Our study also differed from previous studies in terms of
lidocaine dosing. Two of the previous studies used doses
of 100 mg of lidocaine,1,2 2 studies used doses of 200 mg
of lidocaine,5,6 and 1 study administered 2 mg/kg of
lidocaine.3 The current study used 1.5 mg/kg of lidocaine
as the initial treatment dose. Given that the mean weight
of the patients in the lidocaine group was 88.1 kg, the
mean dose of lidocaine administered would have been
132.2 mg. This dose would have been within the dosing
limits reported by other investigators to be successful.
Two studies have investigated the use of amiodarone to
prevent VF after aortic crossclamp removal in cardiac sur-
gery. Samantaray and colleagues6 randomized 34 patients
undergoing CABG to receive 150 mg of amiodarone or pla-
cebo before aortic crossclamp removal. The incidence of
VF in the amiodarone group was 18% versus 65% in the
placebo group (P ¼ .01). In a larger trial, Ayoub and col-
leagues1 randomized 120 patients undergoing CABG to re-
ceive 150 mg amiodarone, 100 mg lidocaine, or placebo 2
minutes before removal of the aortic crossclamp. TheseThe Journal of Thoracic and Carinvestigators found the incidence of VF to be higher in
the groups receiving amiodarone or placebo versus the
group receiving lidocaine (48% vs 45% vs 20% respec-
tively, P ¼ .031). However, they found the energy required
to terminate VF was lower in the patients receiving amio-
darone versus the controls (16  7 J vs 25 8 J; P ¼ .023).
The dose of amiodarone used in this study was signifi-
cantly higher than the dose used in the 2 previous investi-
gations (300 vs 150 mg).1,6 We selected this dose on the
basis of the large volume of distribution of amiodarone
and the expected hemodilution in the CPB reservoir.
Even with this larger dose, we were unable to replicate
the decrease in VF found by Samantaray and
colleagues.6 Our results were similar to those of Ayoub
and colleagues,1 who found no difference in the incidence
of VF, but that VF was more easily terminated in patients
receiving amiodarone.
Our study differs from the described investigations.1,6
Most important, we included a heterogeneous group of
operations, including open cardiac chamber procedures.
The fact that patients undergoing valve operations or septal
myectomy had both a higher incidence of VF and required
a higher number of shocks to terminate VF (Tables 3 and
4) suggests that in addition to the proarrhythmic effects of
myocardial ischemia and reperfusion, gaseous air emboli
from open-chamber procedures and preexisting myocardial
hypertrophy are likely importantmediators of VF after aortic
crossclamp removal in cardiac surgery. A subgroup analysis
of left ventricular mass showed that increasing left ventricu-
lar mass likely plays an important role in the development of
VF and the success of defibrillatory shocks. The finding that
left ventricularmass is a strong predictor of VF and increases
the number of shocks required to terminate VF is important
and may warrant further research. Unfortunately, this was
a secondary finding in our study, and the data were obtained
retrospectively. In addition, less than 70% of the study pa-
tients had echocardiographic data available for review. These
reasons precluded the use of left ventricular mass in our sta-
tistical modeling. The fact that this trial included patients un-
dergoing a variety of surgical procedures in a large, tertiary
care cardiac surgery practice makes our results applicable
to diverse cardiac surgical practice and not just that of pa-
tients undergoing isolated CABG.
In addition, our dosing of amiodarone was higher than
that in previous investigations. However, this may not
have been a large enough dose given the large volume of
distribution of amiodarone combined with hemodilution
from the CPB reservoir. Although the numbers are small
(14 total patients), patients who were taking amiodarone
preoperatively had a significantly decreased incidence of
VF and required fewer shocks to terminate VF. The num-
bers are small and the results must be viewed with caution,
but they suggest that an intravenous bolus of 300 mg of
amiodarone may not be adequate to achieve therapeuticdiovascular Surgery c Volume 144, Number 5 1233
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Mtissue levels in the myocardium. Future studies aimed at
preventing reperfusion VF may focus on preoperative load-
ing of patients with oral amiodarone.
It seems paradoxical that our univariate analyses indicate
that older patients and longer CPB and crossclamp times
seem to be protective against VF. This is a reflection of the
type of operation. The patients undergoing myectomy were
younger and have short CPB and crossclamp times compared
with patients undergoing CABG. However, our data show
that septal myectomy is a strong predictor of reperfusion
VF. Thus, it is the operation type and not the age, or CPB
and crossclamp duration, that predicts VF. That is why older
age and longer CPB and crossclamp times were protective
from VF in univariate but not multivariate models.
Study Limitations
The current trial has some limitations. Despite enrolling
a heterogeneous surgical population, the mean left ventric-
ular ejection fraction was normal. Thus, it is unclear
whether our results are applicable to patients with decreased
left ventricular function. Second, as noted earlier, the dose
of administered amiodarone may not have been high
enough to achieve therapeutic tissue levels given the added
circulatory volume of the CPB circuit. Last, the study pop-
ulation included a large number of patients undergoing sep-
tal myectomy for hypertrophic obstructive cardiomyopathy.
This may be an uncommon patient population for many car-
diac surgical centers.
CONCLUSIONS
When applied to patients undergoing a variety of cardiac
surgical procedures, neither 300 mg of amiodarone nor 1.5
mg/kg of lidocaine administered 3 minutes before aortic
crossclamp removal decreases the incidenceofVF.However,
amiodarone, but not lidocaine, reduces the number of shocks
required to terminate VF after aortic crossclamp removal.
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